Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

First Edition: September 21, 2010

In today's headlines, news about major insurers' plans to stop offering child-only health policies in advance of new rules.

21 Sep 2010

Tips to protect physical health

Fifteen years ago, the non-profit Educational Television Network created Healthy Aging Month to focus attention on the positive aspects of getting older and to encourage people to learn how to increase longevity and avoid preventable declines in physical, mental and emotional health. Healthy aging is of particular interest as life expectancy in the United States continues to rise. According to the Centers for Disease Control and Prevention, in 2007 the life expectancy was 75.4 for men and 80.4 for women .

21 Sep 2010

Crestor suppressed human cancer cells transplanted to mice

A drug commonly prescribed for people with high cholesterol may also be effective in treating prostate cancer, according to new research by Dr. Xiao-Yan Wen at St. Michael's Hospital.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Detailed cholesterol testing for Type 2 diabetes patients is the focus of a newly published article by Atherotech Diagnostics Lab Chief Medical Officer Michael E. Cobble, M.D. The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP® Cholesterol Test from Atherotech.

18 Sep 2010

Society for Vascular Nursing partners with local hospitals to create P.A.D awareness

Approximately 9 million Americans have peripheral arterial disease (P.A.D.), a common and dangerous vascular disease that can lead to heart attack, stroke, amputation and death. Unfortunately, many with the disease do not even know they have it. September is P.A.D. Awareness Month, and the P.A.D. Coalition and the Society for Vascular Nursing are joining forces with local hospitals to inform Americans about the risk factors, warning signs and consequences of P.A.D.

17 Sep 2010

Researchers find bariatric surgery reduces cardiovascular disease risk

Significant weight loss not only improves daily life of morbidly obese woman but also decreases the risk for cardiovascular disease (CVD). However, many people can not lose weight or can not maintain weight loss without help. Bariatric surgery is emerging as a valuable procedure to help morbidly obese individuals lose weight, as studies have shown; it can improve many health profiles and lower mortality. Now, researchers have found another positive impact of significant weight loss after bariatric surgery, it can significantly improve the lipoprotein profiles of women within a year following surgery.

17 Sep 2010

Metabolism imbalance increases asthma risk in children: Research

Even children of a healthy weight who have an imbalanced metabolism due to poor diet or exercise may be at increased risk of asthma, according to new research, which challenges the widespread assumption that obesity itself is a risk factor for asthma.

17 Sep 2010

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

NuGEN Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

16 Sep 2010

Gene network behind hardening of arteries, coronary heart disease identified

A gene network behind hardening of the arteries and coronary heart disease has been identified by a team of scientists from Australia, Europe and the United Kingdom. Their findings expose potential targets for the treatment of heart disease.

16 Sep 2010

ABCB4 gene causes bad cholesterol to accumulate in blood: Research

Scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio have found a gene that causes high levels of bad cholesterol to accumulate in the blood as a result of a high-cholesterol diet.

16 Sep 2010

Eggland's Best supports Susan G. Komen for the Cure's breast cancer advocacy efforts

Eggland's Best, Inc. (EB) is proud to support Susan G. Komen for the Cure®, the world's largest breast cancer advocacy organization. For the first time in the brand's history, Eggland's Best will display the Komen for the Cure's running ribbon logo along with a pink version of their iconic "EB" stamp on their egg varieties during the autumn of 2010.

15 Sep 2010

UT Southwestern receives $8 million NIH grant to study influence of brain and liver on inflammation

An $8 million grant from the National Institutes of Health will enable UT Southwestern Medical Center to investigate how fat tissue "talks" to the brain and the liver to promote inflammation-related disorders such as diabetes, heart disease and obesity.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

Health risk assessments

At various points in our lives, we're curious about our health risks, wondering about our susceptibility for everything from high cholesterol to a deadly inherited disease. We might want to learn more about our risks when we reach a certain age or experience a bout of bad health; when we hear about a friend or co-worker coping with a dreaded illness; or read the latest headlines about disease research.

13 Sep 2010

Resverlogix announces key changes to Phase 2 ASSURE trial

Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.

10 Sep 2010

HealthFitness wellness program helps Eastman employees reduce health risks, lower medical claims

The HealthFitness wellness program offered to Eastman Chemical Company employees helped reduce Eastman employees' health risks and lower their medical claims, resulting in a 3.2 return on investment for every dollar spent on core wellness program components.

10 Sep 2010

Study finds misclassification of risk groups for heart diseases

The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.

10 Sep 2010

Method to predict risk of major coronary event may underestimate risk for millions of Americans: Study

A method that is widely used to predict the risk of a major coronary event may over- or underestimate risk for millions of Americans, according to a study directed by a researcher at the San Francisco VA Medical Center and the University of California, San Francisco.

10 Sep 2010